吉非替尼治疗伴有EGFR基因检测的非小细胞肺癌的文献综合分析  

Meta Analysis of Gefitinib for the Treatment of Non-small Cell Lung Cancer with the Expression ofEGFR Gene

作　　者：李倩琴 李恩泽 詹道友(编辑) 

机构地区：[1]南方医院心胸血管外科,广东广州,510515

出　　处：《医学临床研究》2012年第8期1432-1436,共5页Journal of Clinical Research

摘　　要：【目的】了解吉非替尼治疗非小细胞肺癌肺癌的疗效及生物学特性与治疗疗效的相关性。【方法】在Pubmed和Sciencedirect网站收集了6个伴有EGFR基因检测的非小细胞肺癌使用吉非替尼治疗的前瞻性临床试验进行分析。【结果】分别对吉非替尼治疗的患者特征、患者EGFR基因突变、疗效及不良反应的数据进行列袁并对比分析。有EGFR基因突变患者的CR、PR、SD、PD、RR、DCR、中位无进展生存期、中位总生存期的各项结果均优于总体患者的结果，有EGFR基因突变患者疗效情况比总体患者疗效情况好，提示吉非替尼对有EGFR基因突变患者治疗效果更佳，是吉非替尼治疗NSCLC的优势人群。【结论】吉非替尼的优势人群为亚裔、女性、非吸烟者，吉非替尼的疗效比含铂化疗方案疗效佳，并且吉非替尼对有EGFR基因突变患者治疗效果更佳。[Objective] To understand the efficacy of gefitinib for the treatment of non-small cell lung cancer （NSCLC） and the correlation between biological characteristics and the efficacy. [Methods] Six prospective clinical trails of NSCLC patients with the expression of EGFR gene receiving gefitinib therapy which were collected from Pubmed and ScienceDirect network site were analyzed. [Results]The characteristics, EGFR gene mutation, efficacy and side effects of patients treated with gefitinib were listed and compared. CR, PR, SD, PD, RR, IX;R, mean non-progressive survival time and mean total survival time of patients with EGFR mutation were better than those of total patients. The efficacy of patients with ECJFR mutation was better than total patients. The results suggested that gefitinib for the treatment of pa- tients with EGFR mutation had better efficacy. The NSCLC patients with EGFR mutation were the superior population of gefitinib therapy. [Conclusion] Asian, women and non-smokers are the predominant population of gefitinib. Gefitinib has better efficacy than platinum-based chemotherapy. The efficacy of gefitinib for the treatment of NSCLC patients with EG- FR mutation is better than those without EGFR mutation.

关 键 词：癌 非小细胞肺/药物疗法 受体 表皮生长因子一尿抑胃素 

分 类 号：R730.26[医药卫生—肿瘤]